Vendredi 17 Septembre 2021 de 11h00 à 13h00
Séminaire IRCM

Maria Casanova

CNIO, Madrid

Tissue-resident macrophages: helpers of early-stage lung tumor development”

Contact : Antonio Maraver



Vendredi 10 Décembre 2021 de 11h00 à 12h00
Séminaire IRCM

Pablo José Fernandez

Instituto Madrileño de Estudios Avanzados, Madrid, Espagne

"Molecular perspectives of short-term fasting as a nutritional strategy during cancer development and management”


More details

Vendredi 22 Octobre 2021 de 14h00 à 15h00
Séminaire IRCM

Manuel Collado

Santiago de Compostela University Hospital, Espagne

“Cell senescence in development, regeneration and cancer”

Contact IRCM : Antonio MARAVER

More details


jeudi 27 mai 2021, 11h, Séminaire promotionnel

Chady Jaber

Syntego Inc

“ How to Use the Power of CRISPR in Functional Genomics and Biomarkers Discovery”

This seminar dedicated to researchers at the IRCM will cover the following topics:
    • CRISPR Experimental Design and Optimization (Knock-outs and Knock-ins) 
    • Synthego robust loss of function screens for confident target discovery
    • Using CRISPR to uncover protein functions and pathway analysis

Join us for an interactive session about the latest CRISPR advances and applications. Discover the impact of CRISPR in cancer and genetic disease research.


Inscription obligatoire :

mercredi 5 mai à 11h00, séminaire MAbImprove

Sally Ward

professeur d'immunologie moléculaire et directrice de l'immunologie translationnelle au Centre d'immunologie du cancer de la faculté de médecine de l'Université de Southampton

"Targeting subcellular trafficking pathways to  design antibody-based therapeutics for cancer and autoimmunity"

Professors Sally Ward and Raimund Ober have recently relocated their research group from the USA to Southampton. Their interdisciplinary research program is dedicated to the use of protein engineering to develop novel antibody-based therapeutics.

The identification in the Ward/Ober laboratory of the Fc receptor, FcRn, as a regulator of IgG levels and transport has resulted in significant interest in targeting FcRn in biopharma. Extensive analyses of FcRn behaviour, including subcellular trafficking studies, have led to collaborations with biopharma to develop several therapeutics that are based on modulating the interactions of IgG with FcRn. For example, one such therapeutic (Efgartigimod) that inhibits FcRn activity has been developed in collaboration with Argenx, and has recently been successfully used in phase 3 trials to treat antibody-mediated autoimmune diseases.

"The presentation will cover how a combination of antibody engineering, fluorescence microscopy and mouse disease models have been used to inform the design of therapeutics to modulate the dynamic behavior of antibodies for the treatment of autoimmunity. In particular, the targeting of the MHC Class I-related receptor, FcRn, that recycles and transports IgG to maintain IgG homeostasis will be discussed. The generation of engineered antibody-drug conjugates that are designed to deliver their cytotoxic payload more efficiently to tumor cells will also be presented"

Mercredi 19 Mai à 11h, Séminaire MAbImprove

Julie Bonnereau

PhD student – INSERM U1160, Intestinal Immunity in Inflammation and Cancer - Hôpital Saint Louis, Paris 

« Targeting the CD39/CD73 adenosinergic pathway in human colorectal cancer increased T cell infiltration and tumor destruction in an autologous coculture model »

« The 3IC team works on the intestinal immunity in inflammation and cancer, and more specifically on T cells. The intestine presents a particular immune system, constantly stimulated by exogenous antigens from food, commensal microbiota or pathogens. Specific regulations balance the immune response between tolerance of microbiota and food antigens, and protection against pathogens. This immune homeostasis is crucial and its perturbation are involved in several pathologies. Upon epithelial stress and continuous inflammation, an abnormal proinflammatory immune response can induce autoimmune reactions and chronic inflammation diseases, whereas an excessive tolerant phenotype established an immunosuppressive microenvironment favourable to cancer progression. In this tumor context, an antitumor T cell response is clearly engaged but the upregulation of immunosuppressive markers, like the immune checkpoints, allow the tumor immune escape. Immunotherapies targeting these markers, anti-PD-1 and anti-CTLA-4, were developed but presented a weak efficacy in colorectal cancer (CRC).  New therapeutic strategies are necessary. In this project, we studied the antitumor T cell response involved in human CRC. Based on a prospective cohort, our objectives were to better characterize this response to find new potential target for immunotherapy and test their efficacy in our innovative autologous coculture model. We focused on several different pathways including CD39 and CD73. »

Contact IRCM : Laurent GROS

Vendredi 19 Février, 14h

Adrian Baumann

Nanolive, Genève, Suisse

“Label-free 3D holotomographic live cell imaging at high resolution”

Contact IRCM : Alexandre Djiane

Vendredi 12 Février 14H, séminaire IRCM

Gergely Szakacs

Institute of Cancer Research, Medical University of Vienna, Austria

“Targeting efflux transporters in multidrug resistant cancer: an unfinished business”

"Clinical evidence shows that, following initial response to treatment, drug-resistant cancer cells frequently evolve, and eventually most tumors become resistant to all available therapies. The most straightforward cause of therapy resistance is linked to cellular alterations that prevent drugs to act on their target. Upregulation of cell membrane efflux transporters of the ATP-binding cassette (ABC) superfamily leads to simultaneous resistance against structurally and functionally unrelated chemotherapeutic agents. In particular, P-glycoprotein (Pgp, MDR1), the product of ABCB1 gene, was shown to be expressed in several drug resistant malignancies. Based on the correlation of P-glycoprotein expression and function with unfavorable treatment response, it is universally accepted that pharmacological modulation of the MDR phenotype has the potential to significantly increase the efficacy of currently available anticancer therapies. Unfortunately, despite a few early successes, clinical trials conducted with Pgp inhibitors did not fulfill this expectation, failing to confirm clinical benefit. Failure of the trials led to a setback in research, and the shutdown of the pharmaceutical development of transporter inhibitors for the improvement of anticancer therapy. Yet the “transporter problem” has not vanished, as evidenced by new studies supporting the relevance and benefit of research on the role of ABC transporters in clinical drug resistance. Failure of the inhibitors has boosted research in other directions, exploring the possibility to evade efflux, or to exploit the paradoxical sensitivity associated with efflux-based drug resistance mechanisms. In this talk I will describe new approaches to combating multidrug-resistant cancer, including the development of drugs that engage, evade or exploit efflux by P-glycoprotein."

Contact IRCM : Charles Theillet

Le séminaire sera diffusé par Zoom. Un lien sera envoyé par mail quelques jours avant la date
This will be a Zoom webinar. A link will be sent by email in due time.


© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés